Future-Ready Pharma Procurement Strategy for Global Businesses

Introduction

A pharma procurement strategy is becoming increasingly important as pharmaceutical companies, healthcare distributors, hospitals, importers, and global buyers manage complex international supply chains. Procurement today is no longer limited to finding products at competitive prices. Buyers must also evaluate supplier reliability, regulatory compliance, product quality, lead times, documentation, logistics, and supply continuity.

For businesses sourcing from international markets, a structured procurement sourcing process can reduce operational risks while improving cost control and supplier performance. India has become an important pharmaceutical manufacturing and export hub, supplying medicines, active pharmaceutical ingredients (APIs), vaccines, biological products, and other healthcare products to markets worldwide. A future-ready approach therefore combines supplier diversification, digital procurement, quality assurance, regulatory preparedness, demand forecasting, and sustainable sourcing.

India’s Position in the Global Pharmaceutical Market

India plays a significant role in the global pharmaceutical supply chain, particularly in generic medicines, formulations, APIs, and vaccines. According to Pharmexcil, India's pharmaceutical exports reached approximately US$30.47 billion in FY2024–25, representing around 9.4% year-on-year growth. India's export ecosystem is supported by a large manufacturing base, skilled pharmaceutical workforce, established regulatory capabilities, and extensive international trade relationships. The country's pharmaceutical industry also supplies products to highly regulated markets, requiring manufacturers and exporters to maintain rigorous quality and compliance systems.

For international buyers, India's role provides sourcing opportunities across finished formulations, bulk drugs, APIs, vaccines, medical-related products, and selected Surgical Products.

Key Product Categories and Segments

A comprehensive pharma procurement strategy should begin by identifying the exact product category, required specifications, regulatory requirements, and target market.

1.Pharmaceutical Formulations and Biological Products

Drug formulations and biological products represent the largest category of India's pharmaceutical exports. Pharmexcil reported approximately US$22.93 billion in exports from this category during FY2024–25, accounting for about 75% of total pharmaceutical exports.

2.APIs and Bulk Drugs

Active pharmaceutical ingredients and bulk drugs are essential components of the global pharmaceutical manufacturing ecosystem. International buyers often source these products based on quality specifications, regulatory approvals, production capacity, batch consistency, and documentation.

3.Vaccines

Vaccines remain another important export segment. Buyers must consider temperature-controlled logistics, product registration, quality certifications, and cold-chain requirements when developing procurement plans.

4.Surgical and Healthcare Products

Surgical Products form a smaller portion of India's pharmaceutical export basket but remain relevant to healthcare procurement. Buyers may evaluate products based on material specifications, sterilization requirements, packaging, regulatory standards, and intended market.

Export Performance and Statistics

India's pharmaceutical export performance has expanded steadily over recent years. The Ministry of Commerce reported that drugs and pharmaceutical exports increased from approximately US$15.4 billion in FY2014–15 to US$30.5 billion in FY2024–25.

The following figures provide a useful snapshot of the FY2024–25 export landscape:

Category / Region	Approx. FY2024–25 Value	Share / Indicator
Total pharmaceutical exports	US$30.47 billion	100%
Drug formulations & biologicals	US$22.93 billion	75.26%
Bulk drugs & intermediates	US$4.87 billion	~15.98%
Vaccines	US$1.22 billion	~4.01%
Surgical products	—	~2.48% share
NAFTA region	US$11.46 billion	37.63%
Europe	Approx. US$5.77 billion	18.92%
Africa	Approx. US$3.93 billion	12.91%
Latin America & Caribbean	Approx. US$2.04 billion	6.68%

Figures are based on FY2024–25 data reported by Pharmexcil and DGCIS; regional values are approximate calculations from reported shares. These figures demonstrate why global procurement teams need structured supplier evaluation and market-specific sourcing plans.

Major Export Destinations

India's pharmaceutical exports serve a diverse group of international markets. The NAFTA region accounted for approximately 37.63% of India's pharmaceutical exports in FY2024–25, making it the largest regional destination. Europe accounted for about 18.92%, while Africa represented approximately 12.91%. The United States remains particularly important, accounting for approximately 34.51% of India's pharmaceutical exports according to Pharmexcil's FY2024–25 export data. Other significant destinations include the United Kingdom, Brazil, France, and markets across Africa, Asia, Latin America, and the Middle East. For global buyers, this geographic diversity can support supplier diversification and reduce excessive dependence on a single sourcing market.

Strengths of Indian Pharmaceutical Exports

1.Cost-Efficient Manufacturing

India's large manufacturing ecosystem can provide competitive production economics across several pharmaceutical categories. Scale, established supplier networks, and an experienced workforce contribute to manufacturing efficiency.

2.Skilled Workforce

The pharmaceutical industry depends on specialists in formulation development, quality control, production, regulatory affairs, engineering, and supply-chain management. India's established talent pool supports a broad manufacturing ecosystem.

3.Established Export Infrastructure

Pharmaceutical exporters operate within established logistics and documentation networks serving multiple global destinations. India's wider logistics infrastructure has also improved, with the World Bank's 2023 Logistics Performance Index ranking India 38th among 139 countries.

4.Diverse Supplier Ecosystem

Buyers can evaluate manufacturers and suppliers across formulations, APIs, intermediates, vaccines, healthcare products, and other pharmaceutical categories. This diversity can support multi-supplier procurement models.

Challenges in Pharmaceutical Procurement

International pharmaceutical procurement involves challenges that cannot be addressed through price negotiation alone. Regulatory compliance is one of the most important considerations. Different countries have different registration requirements, quality standards, labeling rules, import procedures, and documentation requirements. A supplier that meets requirements in one market may require additional approvals for another. Price volatility can also affect procurement decisions. Changes in raw-material costs, energy prices, transportation expenses, currency exchange rates, and regulatory costs can influence landed product costs. Supply continuity is another major concern. Buyers should assess manufacturing capacity, inventory policies, lead times, backup suppliers, quality history, and logistics arrangements before entering long-term agreements. Competition also continues to increase across global pharmaceutical markets. Procurement teams therefore need to evaluate total cost of ownership rather than focusing only on the initial purchase price.

Building a Future-Ready Procurement Sourcing Process

A modern procurement sourcing process can be structured around several interconnected stages. First, buyers should define product specifications, volumes, target markets, regulatory requirements, packaging needs, and delivery schedules.

Second, suppliers should be screened according to manufacturing capability, certifications, quality systems, export experience, documentation, and production capacity. Third, commercial evaluation should consider product price, freight, duties, insurance, payment terms, minimum order quantities, and other landed costs.

Fourth, quality and regulatory due diligence should be completed before final supplier selection. Depending on the product and destination, this may include audits, certificates, product documentation, testing requirements, and registration checks.

Finally, procurement teams should continuously monitor supplier performance using measurable indicators such as delivery reliability, quality consistency, response time, documentation accuracy, and cost changes.

Sustainability and Future Outlook

Sustainability is becoming increasingly relevant to pharmaceutical supply chains. Buyers are paying greater attention to energy efficiency, responsible waste management, recyclable packaging, water usage, emissions, and responsible sourcing practices. Digital technologies are also changing procurement operations. Supplier databases, electronic documentation, demand forecasting, inventory analytics, and supply-chain visibility tools can help procurement teams make decisions using more timely information. The future of pharmaceutical sourcing is likely to emphasize resilience alongside cost efficiency. Companies that diversify suppliers, improve visibility, strengthen compliance processes, and use data-driven procurement can better prepare for changing market conditions. India's pharmaceutical export growth also indicates continued international demand. With exports reaching approximately US$30.47 billion in FY2024–25, the sector provides a substantial base for international sourcing and trade relationships.

FAQs

1.What is a pharma procurement strategy?

A pharma procurement strategy is a structured approach to purchasing pharmaceutical products, APIs, healthcare products, and related materials while considering cost, quality, compliance, supplier reliability, logistics, and supply continuity.

2.Why is the procurement sourcing process important in pharmaceuticals?

The procurement sourcing process helps buyers systematically identify, evaluate, qualify, negotiate with, and monitor suppliers. This is particularly important in pharmaceuticals because quality and regulatory requirements can directly affect market access.

3.What pharmaceutical products can global buyers source from India?

Global buyers can source various products, including finished formulations, APIs, bulk drugs, intermediates, vaccines, biological products, and selected Surgical Products, subject to applicable regulatory requirements.

4.What should buyers check before selecting a pharmaceutical supplier?

Buyers should examine manufacturing capabilities, quality systems, certifications, regulatory documentation, production capacity, export history, product specifications, lead times, pricing, and supply continuity.

5.How can pharmaceutical procurement become more resilient?

Businesses can improve resilience through supplier diversification, accurate demand forecasting, safety-stock planning, digital supply-chain visibility, regulatory monitoring, and clearly defined supplier-performance metrics.

Conclusion

Global pharmaceutical procurement is evolving from a price-focused purchasing function into a strategic supply-chain discipline. Buyers increasingly need to balance cost, quality, compliance, resilience, sustainability, and delivery performance when developing international sourcing programs. India's strong export base, diverse manufacturing ecosystem, skilled workforce, and established international market presence make it an important sourcing market for global pharmaceutical businesses. At the same time, successful international procurement requires careful supplier qualification, regulatory due diligence, logistics planning, and continuous performance monitoring. A pharma procurement strategy built around these principles can help global businesses create more transparent, resilient, and efficient sourcing operations while responding to changing pharmaceutical market requirements.